MedTrace Logo

Is Serum Irisin Level a Biomarker in Diabetic Polyneuropathy?

NCT07734597 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2026-07-29

No results posted yet for this study

Summary

Diabetic polyneuropathy is a common complication of type 2 diabetes mellitus associated with sensory impairment and functional disability. Irisin is a myokine that has been implicated in glucose metabolism and neuroprotection. This prospective observational case-control study aims to evaluate serum irisin concentrations in patients with diabetic polyneuropathy compared with diabetic patients without neuropathy and healthy controls, and to investigate whether serum irisin may serve as a biomarker for diabetic polyneuropathy.

Conditions

  • Polyneuropathies
  • Diabetic Complications Neurological
  • Diabetes Mellitus Type 2

Sponsors & Collaborators

  • GÜLDEN ANATACA

    lead OTHER

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-30
Primary Completion
2026-07-30
Completion
2026-09-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07734597 on ClinicalTrials.gov